Company profile

John A. Scarlett
Incorporated in
Fiscal year end
Former names
Geron Corporation
IRS number

GERN stock data

FINRA relative short interest over last month (20 trading days) ?


28 May 20
6 Jun 20
31 Dec 20


Company financial data Financial data

Quarter (USD) Mar 20 Dec 19 Sep 19 Jun 19
Revenue 52K 171K 131K 101K
Net income -16.36M -29.07M -15.18M -14.24M
Diluted EPS -0.08 -0.15 -0.08 -0.08
Net profit margin -31452% -17000% -11588% -14098%
Operating income -16.87M -30.01M -15.97M -15.22M
Net change in cash 6.65M -7.11M 3.04M 10.91M
Cash on hand 20.29M 13.64M 20.75M 17.71M
Annual (USD) Dec 19 Dec 18 Dec 17 Dec 16
Revenue 460K 1.07M 1.07M 6.16M
Net income -68.55M -27.02M -27.92M -29.54M
Diluted EPS -0.36 -0.15 -0.18 -0.19
Net profit margin -14902% -2534% -2621% -479%
Operating income -72.51M -31.07M -29.26M -30.65M
Net change in cash 3.07M -5.76M 3.53M -8.44M
Cash on hand 13.64M 10.58M 16.34M 12.81M

Financial data from Geron earnings reports

Date Owner Security Transaction Code $Price #Shares $Value #Remaining
31 Mar 20 Spiegel Robert J. Common Stock Grant Aquire A 0 6,039 0 103,001
12 Feb 20 Olivia Kyusuk Bloom Employee Stock Option Common Stock Grant Aquire A 1.295 291,375 377.33K 291,375
12 Feb 20 John A Scarlett Employee Stock Option Common Stock Grant Aquire A 1.295 582,750 754.66K 582,750
12 Feb 20 Stephen Rosenfield Employee Stock Option Common Stock Grant Aquire A 1.295 291,375 377.33K 291,375
12 Feb 20 Melissa Kelly Behrs Employee Stock Option Common Stock Grant Aquire A 1.295 291,375 377.33K 291,375
30.1% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 116 120 -3.3%
Opened positions 13 14 -7.1%
Closed positions 17 15 +13.3%
Increased positions 32 38 -15.8%
Reduced positions 30 27 +11.1%
13F shares
Current Prev Q Change
Total value 244.67M 253.73M -3.6%
Total shares 61.25M 63.01M -2.8%
Total puts 266.6K 494.7K -46.1%
Total calls 178.9K 413.7K -56.8%
Total put/call ratio 1.5 1.2 +24.6%
Largest owners
Shares Value Change
BLK BlackRock 15.67M $18.64M +0.5%
FMR 13.41M $15.95M -13.7%
Vanguard 10.37M $12.34M +4.5%
STT State Street 3.73M $4.44M +2.6%
Geode Capital Management 2.74M $3.26M +10.6%
NTRS Northern Trust 2.29M $2.73M +4.8%
Two Sigma Investments 1.59M $1.9M +74.2%
Charles Schwab Investment Management 1.21M $1.44M +1.6%
BK Bank Of New York Mellon 838.96K $998K +2.9%
Nuveen Asset Management 691.97K $824K -0.1%
Largest transactions
Shares Bought/sold Change
FMR 13.41M -2.13M -13.7%
MS Morgan Stanley 103.35K -726.9K -87.6%
Two Sigma Investments 1.59M +679.37K +74.2%
Two Sigma Advisers 668.61K +624.15K +1403.8%
BAC Bank of America 608.48K -525.1K -46.3%
Vanguard 10.37M +445.04K +4.5%
Geode Capital Management 2.74M +263.35K +10.6%
Alpine Global Management 0 -168.67K EXIT
IVZ Invesco 154.3K +154.3K NEW
Oxford Asset Management 0 -151.97K EXIT

Financial report summary

  • Completion of current clinical trials of imetelstat, including the Phase 3 portion of IMerge, and commencement of potential future clinical trials of imetelstat could be interrupted, further delayed or abandoned for a variety of reasons.
  • If we encounter difficulties enrolling or retaining patients in clinical trials of imetelstat, including in the Phase 3 portion of IMerge, clinical development and commercialization activities could be further delayed or otherwise adversely affected, which would cause our business and business prospects to be severely harmed, and we might cease operations.
  • Imetelstat may cause, or have attributed to it, undesirable or unintended side effects or other adverse events that could further delay or prevent the commencement and/or completion of clinical trials for imetelstat, further delay or prevent its regulatory approval, or limit its commercial potential.
  • Results and data we disclosed from prior non-clinical studies and clinical trials may not predict success in later clinical trials, and we cannot assure you that any ongoing or future clinical trials of imetelstat will lead to similar results and data that could potentially enable us to obtain any regulatory approvals.
  • Interim, “snapshot,” “top-line,” and preliminary data or statistical analyses from clinical trials that we announce or publish from time-to-time may change as more patient data become available, may not be similar to the final data, and are subject to audit and verification procedures that could result in material changes in the final data. Thus, such preliminary data should be considered carefully and with caution and not relied upon as indicative of future clinical results.
  • We have limited experience as a company in conducting large-scale, late-stage clinical trials, such as the Phase 3 portion of IMerge or potential future similar trials, and no prior experience as a company in those functional areas that would be required for the successful commercialization of our sole product candidate, imetelstat.
  • A Fast Track designation by the FDA, such as the Fast Track designations received for imetelstat for MDS and relapsed/refractory MF, does not guarantee approval and may not lead to a faster development, regulatory review or approval process.
  • Failure to achieve continued compliance with government regulations could delay or halt potential commercialization of imetelstat.
  • We currently have no source of product revenue and may never become consistently profitable.
  • Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.
  • We expect imetelstat to remain our sole product candidate for the foreseeable future. If we are unable to successfully develop or commercialize imetelstat, our business and business prospects would be severely harmed, which might cause us to cease operations.
  • If we are unable to establish potential future collaborative arrangements for imetelstat, we may have to delay, alter or abandon our imetelstat development and commercialization plans.
  • We may not be able to obtain or maintain sufficient insurance on commercially reasonable terms or with adequate coverage against potential liabilities in order to protect ourselves against product liability claims or claims related to clinical trial conduct.
  • We and certain of our officers have been named as defendants in putative securities class action lawsuits. These lawsuits, and potential similar or related lawsuits, could result in substantial damages, divert management’s time and attention from our business, and have a material adverse effect on our results of operations. These lawsuits, and any other lawsuits to which we are subject, will be costly to defend or pursue and are uncertain in their outcome.
  • We may be subject to third-party litigation, and such litigation would be costly to defend or pursue and uncertain in its outcome.
  • Business interruptions by natural disasters and other events beyond our control could negatively impact our business.
  • Obtaining and maintaining our patent rights depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.
  • Patent terms may be inadequate to protect our competitive position on imetelstat for an adequate amount of time.
  • Changes in U.S. or foreign patent law or interpretations of such patent laws could diminish the value of our patents in general, thereby impairing our ability to protect our technologies and imetelstat.
  • Challenges to our owned or licensed patent rights would result in costly and time-consuming legal proceedings that could prevent or limit development of imetelstat.
  • We may not be able to protect our intellectual property rights throughout the world.
  • We may be subject to infringement claims that are costly to defend, and such claims may limit our ability to use disputed technologies and prevent us from pursuing research, development, manufacturing or commercialization of imetelstat.
  • We may become involved in disputes with past or future collaborator(s) over intellectual property inventorship, ownership or use, and publications by us, or by investigators, scientific consultants, research collaborators or others. Such disputes could impair our ability to obtain patent protection or protect our proprietary information, which, in either case, could have a significant impact on our business.
  • Much of the information and know-how that is critical to our business is not patentable, and we may not be able to prevent others from obtaining this information and establishing competitive enterprises.
  • Significant disruptions of information technology systems, including cloud-based systems, or breaches of data security could adversely affect our business.
  • Changes in and failures to comply with U.S. and foreign privacy and data protection laws, regulations and standards may adversely affect our business, operations and financial performance.
  • Historically, our stock price has been extremely volatile.
  • We may fail to continue to meet the listing standards of Nasdaq, and as a result our common stock may be delisted, which could have a material adverse effect on the liquidity of our common stock.
  • The sale of a substantial number of shares may adversely affect the market price of our common stock.
  • Our undesignated preferred stock may inhibit potential acquisition bids; this may adversely affect the market price of our common stock and the voting rights of holders of our common stock.
  • Provisions in our charter, bylaws and Delaware law may inhibit potential acquisition bids for us, which may prevent holders of our common stock from benefiting from what they believe may be the positive aspects of acquisitions and takeovers.
  • Failure to achieve and maintain effective internal controls in accordance with Section 404 of the Sarbanes-Oxley Act of 2002 could have a material adverse effect on our business and stock price.
  • Competitors may develop products, product candidates or technologies that are superior to or more cost-effective than ours, which may significantly impact the development and commercial viability of imetelstat, which would severely and adversely affect our financial results, business and business prospects, and the future of imetelstat, and might cause us to cease operations.
  • If acceptable prices or adequate reimbursement for imetelstat is not obtained, the use of imetelstat could be severely limited.
  • The adoption of health policy changes and health care reform in the United States may adversely affect our business and financial results.
  • If we fail to comply with federal, state and foreign healthcare laws, including fraud and abuse, transparency, and health information privacy and security laws, we could face substantial penalties and our business, results of operations, financial condition and prospects could be adversely affected.
Management Discussion
  • Our results of operations have fluctuated from period to period and may continue to fluctuate in the future. Results of operations for any period may be unrelated to results of operations for any other period. Thus, historical results should not be viewed as indicative of future operating results. For example, in 2015 we reported net income for the first time due to recognition of revenue in connection with the upfront payment from Janssen under the Collaboration Agreement. Effective September 28, 2018, the Collaboration Agreement with Janssen was terminated. As a result, we will not receive any milestone payments or royalties from Janssen for the development or commercialization of imetelstat. In addition, we expect to incur increasing operating losses in the future as we support two Phase 3 clinical trials of imetelstat, the ongoing Phase 3 portion of IMerge and the planned Phase 3 clinical trial in refractory MF. We are subject to risks common to companies in our industry and at our stage of development, including, but not limited to, risks inherent in research and development efforts, including the development, manufacture, regulatory approval for and commercialization of, imetelstat, uncertainty of non-clinical and clinical trial results or regulatory approvals or clearances, the future development of imetelstat by us, including any future efficacy or safety results that may cause the benefit-risk profile of imetelstat to become unacceptable, overcoming disruptions and/or delays due to the COVID-19 pandemic, our need for future capital, enforcement of our patent and proprietary rights, reliance upon our consultants, licensees, investigators and other third parties, and potential competition. In order for imetelstat to be commercialized, we must conduct non-clinical tests and clinical trials to demonstrate the safety and efficacy of imetelstat, obtain regulatory approvals or clearances and enter into manufacturing, distribution and marketing arrangements, as well as obtain market acceptance. We do not expect to receive revenue based on sales of imetelstat for many years, if at all.
Content analysis ?
H.S. senior Avg
New words: AbbVie, absenteeism, abstract, add, age, Aid, aimed, allegedly, allele, annuity, antibody, appointed, Aprea, arisen, ASA, Asia, assumption, Astex, ATM, AXL, backbone, BCLW, BCLXL, bemcentinib, BerGenBio, Biomedicine, BioTime, body, Brexit, carryback, chance, chosen, chronic, circulating, circumstance, clone, closure, composition, compulsory, concept, confidence, conserve, contact, County, criterion, cured, cyber, Dacogen, Dear, debilitating, deciliter, died, discretionary, disordered, disproportionately, distancing, divested, divestiture, DNMT, documentary, drenching, driven, driver, dynamic, dysfunctional, dysplastic, earliest, economy, elderly, elevated, embryonic, enlarge, enrichment, equitable, equivalent, essential, expedient, export, expressly, fever, fewer, fight, format, free, fulfill, Governor, headache, heavily, home, hospital, immature, inadvertent, incident, indirect, inspection, invited, Journal, lapse, LCL, left, lessor, lifespan, lifetime, lifted, line, lineage, living, longest, malignant, Mateo, methyltransferase, microscope, misleading, missed, moderately, modest, morphology, motion, myeloproliferative, narrowly, navitoclax, neoplasm, Nineteen, nonpayment, nonprovisional, North, novelty, official, optimal, Otsuka, outbreak, outreach, owner, pandemic, people, permanent, poorer, posed, postpone, postponed, postponement, precursor, prejudice, prescribed, presence, proactively, problem, progenitor, projected, proliferate, proliferation, proof, proper, provoke, publicly, Reblozyl, reconsider, reevaluating, referendum, regimen, regular, rejection, remote, remotely, renewal, rescinded, restitution, Revlimid, RS, San, scar, serving, shareholder, shelter, shift, sideroblast, site, situation, slowdown, spliceosome, spread, Squibb, statutory, stop, strong, stronger, subpopulation, supplement, susceptible, telecommute, temporarily, tenant, TI, tissue, Transformation, unavoidable, uncontrolled, underwriting, underwritten, unjust, unsatisfactory, upregulation, Urgent, variant, verification, viable, Vidaza, virtual, voluntarily, white, widespread, withholding, word, world
Removed: ACA, Accountability, acid, acting, adjusted, adjustment, American, Amgen, aminopeptidase, announcement, attempting, automatic, average, back, behalf, billing, Bipartisan, Blueprint, budget, cDNA, checkpoint, Children, circumvent, circumvented, close, CMS, coding, collecting, complicating, conceal, concealing, Concurrently, consisted, constitutionality, construction, consult, consumed, convenience, daratumumab, deacetylase, declared, declined, defraud, delete, delivery, detailed, discomfort, donut, Education, electorate, elimination, embezzling, Encountering, entirety, exact, executing, falsifying, family, Fas, feasible, feedback, flat, FLT, fraudulent, funded, gap, gave, Genmab, genomic, heat, hedgehog, HIPAA, histone, HITECH, holding, hole, immune, inaccurate, IND, induce, instability, intensely, isolated, Judge, kind, knowingly, learn, LFT, liable, ligand, loosen, mandate, mandatory, marginal, marketability, meaningfully, medically, MLV, modifying, Molecular, mTOR, Myriad, nationwide, negotiating, nominal, Notwithstanding, NS, obstructing, occupied, offense, orally, oversee, path, Pathology, pathway, pentraxin, percentage, permitting, PIM, planning, pocket, Portability, preempted, procedure, prohibit, promulgated, pronouncement, proposal, proteasome, published, purported, qualifying, Qualitative, Quantitative, qui, receptor, recombinant, recommendation, Reconciliation, referral, released, remuneration, renovated, repeal, repealing, requesting, resolution, retinoic, reviewed, reward, romiplostim, ruling, safeguarding, satiety, scheme, shock, signaling, slowly, SMAC, SMO, soliciting, sotatercept, stay, stealing, suggested, Summary, Sunshine, superfamily, Supreme, suspend, talacotuzumab, tam, Taxpayer, titled, top, tosedostat, TPO, transitioning, transmission, trillion, tyrosine, unconstitutional, universal, unnecessary, upheld, urge, voluntary, voted, week, weighted, whistleblower, willfully